Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
CRISPR Therapeutics AG
Scientific Title
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies